Resistance to antiretrovirals in HIV-infected pregnant women

Journal of Clinical Virology

Volumn 45, Issue 1, 2009, Pages 39-42

  Weinberg, Adriana ^a,b   Forster Harwood, Jeri ^a   McFarland, Elizabeth J ^a   Pappas, Jennifer ^c   Davies, Jill K ^b   Kinzie, Kay ^b   Barr, Emily A ^a   Paul, Suzanne M ^a   Salbenblatt, Carol R ^c   Soda, Elizabeth ^a   Vazquez, Anna ^a   Levin, Myron J ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO HOSPITAL   (United States)

^c CHILDREN S HOSPITAL   (United States)

Author keywords

Antiretroviral resistance; HIV; MTCT; Pregnancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RECORD REVIEW; PREGNANT WOMAN; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LAMIVUDINE; MUTATION; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RETROSPECTIVE STUDIES; VIRAL LOAD; ZIDOVUDINE;

EID: 67349163589     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2009.02.009     Document Type: Article

References (39)

1. Cooper E.R., Charurat M., Burns D.N., Blattner W., and Hoff R. Trends in antiretroviral therapy and mother-infant transmission of HIV. The Women and Infants Transmission Study Group. J Acquir Immune Defic Syndr 24 May (1) (2000) 45-47
2. Dorenbaum A., Cunningham C.K., Gelber R.D., Culnane M., Mofenson L., Britto P., et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA 288 July (2) (2002) 189-198
3. Bannister W.P., Cozzi-Lepri A., Clotet B., Mocroft A., Kjaer J., Reiss P., et al. Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study. J Acquir Immune Defic Syndr 48 July (3) (2008) 324-333
4. Boucher C.A. SPREAD. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS 22 March (5) (2008) 625-635
5. Grant R.M., Hecht F.M., Warmerdam M., Liu L., Liegler T., Petropoulos C.J., et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 288 July (2) (2002) 181-188
6. Little S, Frost S, Smith D, May S, Parkin N, Richman D, et al. Transmission of HIV drug resistance and treatment response. 14th Conference on Retroviruses and Opportunistic Infections 2007: Los Angeles, CA, February 25-28.
7. Little S.J., Frost S.D., Wong J.K., Smith D.M., Pond S.L., Ignacio C.C., et al. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J Virol 82 June (11) (2008) 5510-5518
8. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 August (6) (2002) 385-394
9. Simon V., Vanderhoeven J., Hurley A., Ramratnam B., Louie M., Dawson K., et al. Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals. AIDS 16 July (11) (2002) 1511-1519
10. Stone D.R., Corcoran C., Wurcel A., McGovern B., Quirk J., Brewster A., et al. Antiretroviral drug resistance mutations in antiretroviral-naive prisoners. Clin Infect Dis 35 October (7) (2002) 883-886
11. Viani R.M., Peralta L., Aldrovandi G., Kapogiannis B.G., Mitchell R., Spector S.A., et al. Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study. J Infect Dis 194 December (11) (2006) 1505-1509
12. Cunningham C.K., Chaix M.L., Rekacewicz C., Britto P., Rouzioux C., Gelber R.D., et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis 186 July (2) (2002) 181-188
13. Duran A.S., Losso M.H., Salomon H., Harris D.R., Pampuro S., Soto-Ramirez L.E., et al. Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis. AIDS 21 January (2) (2007) 199-205
14. Kakehasi F.M., Tupinambas U., Cleto S., Aleixo A., Lin E., Melo V.H., et al. Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy. AIDS Res Hum Retroviruses 23 December (12) (2007) 1515-1520
15. Lyons F.E., Coughlan S., Byrne C.M., Hopkins S.M., Hall W.W., and Mulcahy F.M. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS 19 January (1) (2005) 63-67
16. Paredes R., Cheng I., Kuritzkes D.R., and Tuomala R.E. High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004. AIDS 21 October (15) (2007) 2103-2106
17. Overton E.T., Sungkanuparph S., Nurutdinova D., and Powderly W.G. Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy. AIDS 19 September (13) (2005) 1439
18. Holmes C.B., Zheng H., Martinson N.A., Freedberg K.A., and Walensky R.P. Optimizing treatment for HIV-infected South African women exposed to single-dose nevirapine: balancing efficacy and cost. Clin Infect Dis 42 June (12) (2006) 1772-1780
19. Jourdain G., Ngo-Giang-Huong N., Le Coeur S., Bowonwatanuwong C., Kantipong P., Leechanachai P., et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 351 July (3) (2004) 229-240
20. Lockman S., Shapiro R.L., Smeaton L.M., Wester C., Thior I., Stevens L., et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356 January (2) (2007) 135-147
21. Westreich D., Eron J., Behets F., Horst C., and Van Rie A. Survival in women exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV: a stochastic model. J Infect Dis 195 March (6) (2007) 837-846
22. Chokephaibulkit K., Chaisilwattana P., Vanprapar N., Phongsamart W., and Sutthent R. Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission. AIDS 19 July (11) (2005) 1231-1233
23. Cohan D., Feakins C., Wara D., Petru A., McNicholl I., Schillinger D., et al. Perinatal transmission of multidrug-resistant HIV-1 despite viral suppression on an enfuvirtide-based treatment regimen. AIDS 19 June (9) (2005) 989-990
24. Johnson V.A., Petropoulos C.J., Woods C.R., Hazelwood J.D., Parkin N.T., Hamilton C.D., et al. Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant. J Infect Dis 183 June (11) (2001) 1688-1693
25. Ojesina A.I., Mullins C., Imade G., Samuels J., Sankale J.L., Pam S., et al. Characterization of HIV type 1 reverse transcriptase mutations in infants infected by mothers who received peripartum nevirapine prophylaxis in Jos, Nigeria. AIDS Res Hum Retroviruses 23 December (12) (2007) 1587-1592
26. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 13 October-November (4) (2005) 125-131
27. Johnson V.A., Brun-Vezinet F., Clotet B., Gunthard H.F., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med 16 March-April (1) (2008) 62-68
28. Pellegrin I., Breilh D., Montestruc F., Caumont A., Garrigue I., Morlat P., et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 16 July (10) (2002) 1331-1340
29. Simon V., Ho D.D., and Abdool Karim Q. HIV/AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368 August (9534) (2006) 489-504
30. Van Rompay K.K., Brignolo L.L., Meyer D.J., Jerome C., Tarara R., Spinner A., et al. Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 48 May (5) (2004) 1469-1487
31. Gingelmaier A., Kurowski M., Kastner R., Eberle J., Mylonas I., Belohradsky B.H., et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS 20 August (13) (2006) 1737-1743
32. Manavi K., McDonald A., and Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS 21 March (5) (2007) 643-645
33. Nellen J.F., Schillevoort I., Wit F.W., Bergshoeff A.S., Godfried M.H., Boer K., et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis 39 September (5) (2004) 736-740
34. Stek A.M., Mirochnick M., Capparelli E., Best B.M., Hu C., Burchett S.K., et al. Reduced lopinavir exposure during pregnancy. AIDS 20 October (15) (2006) 1931-1939
35. Deeks S.G., Hoh R., Neilands T.B., Liegler T., Aweeka F., Petropoulos C.J., et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 192 November (9) (2005) 1537-1544
36. Eshleman S.H., Mracna M., Guay L.A., Deseyve M., Cunningham S., Mirochnick M., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 15 October (15) (2001) 1951-1957
37. Church J.D., Hudelson S.E., Guay L.A., Chen S., Hoover D.R., Parkin N., et al. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D. AIDS Res Hum Retroviruses 23 June (6) (2007) 764-768
38. Ly N., Recordon-Pinson P., Phoung V., Srey C., Kruy L.S., Koum K., et al. Characterization of mutations in HIV type 1 isolates from 144 Cambodian recently infected patients and pregnant women naive to antiretroviral drugs. AIDS Res Hum Retroviruses 21 November (11) (2005) 971-976
39. Petch L.A., Hoffman I.F., Jere C.S., Kazembe P.N., Martinson F.E., Chilongozi D., et al. Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naive adults in Malawi. AIDS Res Hum Retroviruses 21 September (9) (2005) 799-805